Last reviewed · How we verify
YZJ-4729
At a glance
| Generic name | YZJ-4729 |
|---|---|
| Sponsor | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery (PHASE2)
- A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery (PHASE3)
- A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery (PHASE2)
- A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YZJ-4729 CI brief — competitive landscape report
- YZJ-4729 updates RSS · CI watch RSS
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd. portfolio CI